Exenatide
Byetta · Bydureon · Exendin-4
The first GLP-1 receptor agonist approved by the FDA for T2D, derived from Gila monster venom with strong glucose-lowering and weight management effects.
Half-Life
~2.4 hours (exenatide), ~2 weeks (extended release)
MW
4186.6 Da
Amino Acids
39 AA
Evidence
High Evidence
Regulatory Status
FDA-approved (Byetta: twice daily, Bydureon: weekly).
In Plain English
A GLP-1 mimic originally discovered in Gila monster saliva — it happens to activate the same receptor as human GLP-1. FDA-approved for diabetes. The ancestor of the modern GLP-1 drug class.
Overview
Exenatide was the first GLP-1 receptor agonist approved for T2D treatment. Derived from exendin-4, a peptide found in Gila monster saliva. Available as twice-daily (Byetta) and weekly formulations (Bydureon). The original proof-of-concept for the GLP-1 agonist drug class.
Common Formats
- Pre-filled pen (twice daily or weekly)
Storage Notes
Refrigerate. Do not freeze.
Looking for multi-compound protocols?
Browse educational protocol discussions that include Exenatide.
Related Compounds
Semaglutide
A GLP-1 receptor agonist with FDA approval for type 2 diabetes and obesity, demonstrating unprecedented weight loss results in clinical trials.
Liraglutide
A once-daily GLP-1 receptor agonist with FDA approval for T2D and obesity, the predecessor to semaglutide with strong clinical evidence.
Tirzepatide
A dual GIP/GLP-1 receptor agonist with FDA approval showing up to 22% weight loss — superior to semaglutide in head-to-head trials.
Educational Disclaimer: All information on this page is for educational and research purposes only. This does not constitute medical advice, diagnosis, or treatment recommendation. Consult a qualified healthcare professional.